These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36134028)

  • 1. A p53 transcriptional signature in primary and metastatic cancers derived using machine learning.
    Keshavarz-Rahaghi F; Pleasance E; Kolisnik T; Jones SJM
    Front Genet; 2022; 13():987238. PubMed ID: 36134028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
    Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
    Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome-wide characterization of the endogenous miR-34A-p53 tumor suppressor network.
    Samuel N; Wilson G; Id Said B; Pan A; Deblois G; Fischer NW; Alexandrova R; Casallo G; Paton T; Lupien M; Gariepy J; Merico D; Hudson TJ; Malkin D
    Oncotarget; 2016 Aug; 7(31):49611-49622. PubMed ID: 27391063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Splicing signature database development to delineate cancer pathways using literature mining and transcriptome machine learning.
    Lee K; Hyung D; Cho SY; Yu N; Hong S; Kim J; Kim S; Han JY; Park C
    Comput Struct Biotechnol J; 2023; 21():1978-1988. PubMed ID: 36942103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 from basic research to clinical applications.
    Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
    Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.
    Ishizawa J; Nakamaru K; Seki T; Tazaki K; Kojima K; Chachad D; Zhao R; Heese L; Ma W; Ma MCJ; DiNardo C; Pierce S; Patel KP; Tse A; Davis RE; Rao A; Andreeff M
    Cancer Res; 2018 May; 78(10):2721-2731. PubMed ID: 29490944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of full coding sequence of the TP53 gene in invasive vulvar cancers: Implications for therapy.
    Kashofer K; Regauer S
    Gynecol Oncol; 2017 Aug; 146(2):314-318. PubMed ID: 28527674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
    Xu-Monette ZY; Medeiros LJ; Li Y; Orlowski RZ; Andreeff M; Bueso-Ramos CE; Greiner TC; McDonnell TJ; Young KH
    Blood; 2012 Apr; 119(16):3668-83. PubMed ID: 22275381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
    Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
    Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
    Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer.
    Chipidza FE; Alshalalfa M; Mahal BA; Karnes RJ; Liu Y; Davicioni E; Martin NE; Mouw KW; Feng FY; Nguyen PL; Muralidhar V
    Clin Genitourin Cancer; 2021 Jun; 19(3):246-254.e5. PubMed ID: 32896505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis.
    Romanovsky E; Kluck K; Ourailidis I; Menzel M; Beck S; Ball M; Kazdal D; Christopoulos P; Schirmacher P; Stiewe T; Stenzinger A; Budczies J
    Cell Death Discov; 2023 Apr; 9(1):126. PubMed ID: 37059713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of
    Chen Y; Zhao W; Bi F; Pan X; Yin L; Zhao C
    Oxid Med Cell Longev; 2022; 2022():1817339. PubMed ID: 35847579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
    Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
    Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer.
    Pallocca M; Goeman F; De Nicola F; Melucci E; Sperati F; Terrenato I; Pizzuti L; Casini B; Gallo E; Amoreo CA; Vici P; Di Lauro L; Buglioni S; Diodoro MG; Pescarmona E; Mazzotta M; Barba M; Fanciulli M; De Maria R; Ciliberto G; Maugeri-Saccà M
    J Transl Med; 2018 Sep; 16(1):247. PubMed ID: 30180862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new genotoxicity assay based on p53 target gene induction.
    Zerdoumi Y; Kasper E; Soubigou F; Adriouch S; Bougeard G; Frebourg T; Flaman JM
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Aug; 789-790():28-35. PubMed ID: 26232255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutated
    Li AM; Boichard A; Kurzrock R
    Cancer Biol Ther; 2020; 21(1):95-100. PubMed ID: 31564192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.